Progesterone Formulations

so / - S- Ex sg nProdo j401 0 10 20 30 40 50 60 70 Tnie WMirutes) Pharmaceutical formulations for oral use in hormone replacement therapy comprising ultra-micronized pmgesterone are disclosed, wherein the ultra-micronized progesterone is combined with a suitable excipient. The preferred excipients c...

Full description

Saved in:
Bibliographic Details
Main Authors CACACE, Janice Louise, PERSICANER, Peter H. R
Format Patent
LanguageEnglish
Published 18.06.2020
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

More Information
Summary:so / - S- Ex sg nProdo j401 0 10 20 30 40 50 60 70 Tnie WMirutes) Pharmaceutical formulations for oral use in hormone replacement therapy comprising ultra-micronized pmgesterone are disclosed, wherein the ultra-micronized progesterone is combined with a suitable excipient. The preferred excipients comprise medium chain fatty acid-glycol esters and a nonionic surfactant comprising a polyethylene glycol fatty acid ester. In some embodiments C8 to C18 fatty acid esters of glycerol and polyethylene glycol are the preferred nonionic surfactants.
Bibliography:Application Number: AU20180222947